Texas biotech Lung Ther­a­peu­tics clos­es $36M Se­ries C to ad­vance clin­i­cal work for or­phan drugs

Hap­py with the first glimpse of ef­fi­ca­cy in one of its or­phan pul­monary treat­ments, Lung Ther­a­peu­tics is march­ing on with a fresh $36 mil­lion raise.

Both new and ex­ist­ing in­vestors par­tic­i­pat­ed in the Se­ries C, though on­ly Dal­las/Fort Worth-based Bios Part­ners has been named. It will pay for a Phase II tri­al of LTI-01 for pa­tients with loc­u­lat­ed pleur­al ef­fu­sions as well as a first-in-hu­man study for its po­ten­tial id­io­path­ic pul­monary fi­bro­sis ther­a­py, LTI-03.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER